雅培新冠快速测试获认证 白宫采购1.5亿套
美国总统特朗普政府向美国雅培(Abbott)(ABT.US)购买1.5亿剂新冠快速测试套,总计7.5亿美元。该快速测试可於15分钟内取得结果,於周三(26日)获美国食品及药物管理局紧急授权批准使用。该测试套大小如一张信用卡,毋须额外工具。公司预计9月可付运千万计剂量的测试套,10月初产量为每月5,000万套。
但雅培的快速测试为抗原测试,在辨别阳性个案表现中会较实验室进行的诊断测试为差。Becton Dickinson and Co及Quidel Corp早前已在市场推出同类抗原测试产品。
雅培股价昨日(27日)升7.9%报111.29美元,於延长交易时段再升3.4%报115.07美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.